Dong-A ST Neurobo Presents Preclinical Data of Obesity Treatment at American Diabetes Association Meeting

IND Submission Scheduled for Phase 1 Clinical Trial in the Second Half of the Year

Dong-A ST and its U.S. new drug development subsidiary Neurobo Pharmaceuticals announced on the 14th that they will present preclinical research data on an obesity treatment drug at the 83rd American Diabetes Association (ADA) conference, held from the 23rd to the 26th at the San Diego Convention Center in the United States.

Dong-A ST and Neurobo Pharmaceuticals will present preclinical research data on 'DA-1726' through two poster and oral presentations.

DA-1726 is a new drug candidate under development as an obesity treatment in the oxyntomodulin analogue class. It acts simultaneously on glucagon-like peptide (GLP)-1 receptors and glucagon receptors to suppress appetite, promote insulin secretion, and increase basal metabolic rate in peripheral tissues, ultimately inducing weight loss and blood glucose control.

Neurobo Pharmaceuticals will reveal that, through two poster and oral presentations, DA-1726 demonstrated superior weight loss effects compared to the GLP-1 analogue semaglutide in obesity animal models, along with observed improvements in indicators related to energy metabolism.

It was confirmed that DA-1726 contributes to fat reduction through the inhibition of fat production caused by glucagon receptor activation in cells induced for adipogenesis. Additionally, repeated administration and glucose tolerance assessments showed that even at minimum blood drug concentration conditions, glucose tolerance was not impaired, suggesting that balanced activity on both receptors can resolve concerns about blood glucose elevation associated with oxyntomodulin-class drugs, the company added.

Neurobo Pharmaceuticals, located in Boston, USA, is a Nasdaq-listed company and serves as the global research and development (R&D) forward base of the Dong-A Socio Group, responsible for the global development and commercialization of DA-1726 and the non-alcoholic steatohepatitis (NASH) treatment 'DA-1241.'

Neurobo Pharmaceuticals plans to submit the global Phase 1 clinical trial investigational new drug application (IND) for DA-1726, developed as an obesity treatment, in the second half of this year.

A Neurobo Pharmaceuticals representative stated, "The presentation at this year's American Diabetes Association conference will be an opportunity to prove the excellence of DA-1726," adding, "Starting with the submission of the global Phase 1 IND in the second half of this year, we plan to initiate the global Phase 1 clinical trial in the first half of 2024."

This content was produced with the assistance of AI translation services.